Form 4: AN2 Therapeutics Chief Legal Officer Joshua Eizen Reports Stock Grant and RSU Vesting
SEC Form 4 Filing
Joshua Eizen, Chief Legal Officer of AN2 Therapeutics, reports the acquisition of 60,000 shares of common stock through a restricted stock unit (RSU) grant and adjustments to existing RSU holdings.
Summary
- Joshua Eizen, Chief Legal Officer of AN2 Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
- On July 10, 2024, Eizen was granted 60,000 restricted stock units (RSUs).
- These RSUs vest in three tranches: 25% on January 1, 2025, 50% on January 1, 2026, and 25% on July 1, 2026, contingent upon continuous service.
- Eizen's holdings also include 30,000 RSUs vesting annually from January 1, 2024.
- The report reflects an adjusted total of 94,833 shares, including 2,386 shares purchased under the company's Employee Stock Purchase Plan on March 31, 2024.
- Eizen has granted a Power of Attorney to certain individuals, including the CEO, CFO, and attorneys from Latham & Watkins LLP, to execute and file SEC forms on his behalf.
Sentiment
Score: 6
Explanation: The document is neutral in tone, simply reporting required information about stock transactions. The RSU grant is a positive sign of incentivizing management, but it's a standard practice.
Positives
- The grant of RSUs to a key executive like the Chief Legal Officer can be seen as an incentive to align their interests with the long-term success of the company.
- The vesting schedule encourages continued service and commitment from the executive.
- Participation in the Employee Stock Purchase Plan demonstrates confidence in the company's future.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's financial performance or future prospects.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency regarding the equity holdings of key personnel.
Stakeholder Impact
- Shareholders are informed about changes in the beneficial ownership of a key executive.
- Employees may be interested in the details of the Employee Stock Purchase Plan.
Key Dates
| Date | Description |
|---|---|
| December 14, 2023 | Date of Power of Attorney execution. |
| January 1, 2024 | Start date for annual vesting of 30,000 RSUs. |
| March 31, 2024 | Date of purchase of 2,386 shares under the Employee Stock Purchase Plan. |
| July 10, 2024 | Date of RSU grant of 60,000 shares. |
| July 12, 2024 | Date of Form 4 filing. |
| January 1, 2025 | First vesting date for 25% of the 60,000 RSU grant. |
| January 1, 2026 | Second vesting date for 50% of the 60,000 RSU grant. |
| July 1, 2026 | Final vesting date for 25% of the 60,000 RSU grant. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.